Denise Wolf

Nov 6, 2024 | cell.com | Michael Campbell |Denise Wolf |Christina Yau |Lamorna Brown-Swigart |Isela R. Gallagher |Zelos Zhu | +20 more

ResultsA total of 69 HER2− patients (40 HR+HER2− and 29 TN) were randomized to receive 4 cycles of pembrolizumab in combination with weekly paclitaxel followed by anthracycline chemotherapy (Pembro+T → AC). In addition, there were 181 HER2− patients (96 HR+HER2− and 85 TN) randomized to the standard neoadjuvant chemotherapy control group (T → AC). We utilized three assay platforms to characterize the tumor immune microenvironment in these patients (Figure 1).

Aug 10, 2023 | onclive.com | Denise Wolf

Denise M. Wolf, PhD, Department of Laboratory Medicine, University of California, San Francisco (UCSF), UCSF Health, discusses research into biomarkers predicting responses to immunotherapy in the phase 2 I-SPY2 trial (NCT01042379) in patients with early-stage breast cancer. At the 2023 ASCO Annual Meeting, investigators presented data on the evaluation of immune subtyping in response predictive subtypes of patients with early-stage breast cancer.